| COR |
Report |
Adjusted EPS (Q3 FY26) |
BEAT |
pred ~$4.42 vs. cons $4.37 |
MEDIUM |
| COR |
Report |
Total Revenue (Q3 FY26) |
MISS |
pred ~$83.4B vs. cons $84.89B |
MEDIUM |
| COR |
Report |
U.S. Healthcare Solutions Segment Revenue (Q3 FY26) |
MISS |
pred ~$73.8B vs. cons $75.0B |
MEDIUM |
| COR |
Guide |
FY2026 Adjusted EPS guidance |
BETTER |
guide ~$17.85-$18.05 (mid $17.95) vs. cons $17.85 (FY2026) |
MEDIUM |
| COR |
Guide |
FY2026 Revenue growth guidance |
UNCHANGED |
guide ~5% (4-6% range reaffirmed) vs. cons ~5.1% (FY2026) |
MEDIUM |
| COR |
Guide |
U.S. Healthcare Solutions operating income growth guidance |
UNCHANGED |
guide ~15% (14-16% range reaffirmed) vs. cons ~14% (FY2026) |
MEDIUM |
| COR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
MEDIUM |
| COR |
Return |
5-day cumulative residual |
+0.5% (FADE) |
An EPS beat driven mainly by buybacks/cost control plus reaffirmed (not raised) FY revenue guidance should spark an initial relief rally given the stock's pre-print underperformance vs. SPY (-4% into the print) and post-May de-risked positioning. But this would be the third straight quarter of revenue undershoot on WAC/IRA, mail-order biosimilar mix-shift and decelerating GLP-1 growth, so sell-side analysts are likely to trim FY27/out-period organic revenue and gross-profit-dollar assumptions even while nudging EPS estimates up for the buyback tailwind — a classic 'lower-quality beat' pattern that fades initial upside over the week as the implicit revenue-guide cut (still officially 4-6% but tracking toward the low end) gets modeled through. |
LOW |